Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1909 |
Name | melanoma |
Definition | A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer melanoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00338377 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin | Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT00492505 | Phase II | Cisplatin + Sorafenib + Tamoxifen | Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma | Unknown status | USA | 0 |
NCT00538005 | Phase Ib/II | Bevacizumab + Oxaliplatin + Sorafenib | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | Unknown status | USA | 0 |
NCT00700882 | Phase II | Dasatinib | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00925132 | Phase Ib/II | Decitabine + Panobinostat + Temozolomide | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | Terminated | USA | 0 |
NCT00976573 | Phase II | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Everolimus + Paclitaxel | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | Completed | USA | 0 |
NCT01028222 | Phase II | Nilotinib | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation | Completed | USA | SWE | NLD | ITA | ESP | DEU | CHE | CAN | BRA | BEL | AUS | ARG | 2 |
NCT01176474 | Phase I | NY-ESO-1 peptide vaccine Ipilimumab Nivolumab | A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | Completed | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01239134 | Phase I | TRX518 | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | Completed | USA | 0 |
NCT01258855 | Phase II | Aldesleukin Aflibercept | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01274338 | Phase III | Ipilimumab Interferon alpha-2b | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | Active, not recruiting | USA | CAN | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01303341 | Phase I | Riluzole + Sorafenib | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma | Active, not recruiting | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01321437 | Phase II | Axitinib | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Completed | USA | 0 |
NCT01323517 | Phase II | Dactinomycin + Ipilimumab + Melphalan | Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | Completed | USA | 0 |
NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT01358331 | Phase I | MK-8353 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | Terminated | 0 | |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01409174 | Phase Ib/II | Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | Terminated | USA | 0 |
NCT01425008 | Phase I | Tovorafenib | Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma | Completed | USA | GBR | 0 |
NCT01436656 | Phase I | Encorafenib | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Completed | USA | NOR | FRA | ESP | CHE | AUS | 1 |
NCT01449279 | Phase I | Ipilimumab | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | Completed | USA | 0 |
NCT01480154 | Phase I | Hydroxychloroquine + MK2206 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01495988 | Phase II | Bevacizumab Vemurafenib | Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | Terminated | USA | 0 |
NCT01497808 | Phase Ib/II | Ipilimumab | RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma | Completed | USA | 0 |
NCT01512251 | Phase Ib/II | Buparlisib + Vemurafenib | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | Completed | USA | 0 |
NCT01519323 | Phase I | Vemurafenib | BRIM-P | Terminated | USA | SVK | POL | ITA | ISR | GBR | FRA | ESP | DEU | AUS | 0 |
NCT01533948 | Phase II | Axitinib | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery | Terminated | USA | 0 |
NCT01543698 | Phase Ib/II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | CHE | CAN | BEL | AUS | 1 |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01565837 | Phase II | Ipilimumab | Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma | Unknown status | USA | 0 |
NCT01585415 | Phase I | Vandetanib | Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | Terminated | USA | 0 |
NCT01586195 | Phase II | Vemurafenib | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | Terminated | USA | 0 |
NCT01603212 | Phase Ib/II | Aldesleukin + Alpha 2 Interferon + Vemurafenib | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | Completed | USA | 0 |
NCT01619774 | Phase II | Dabrafenib + Trametinib | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | Completed | USA | 0 |
NCT01621490 | Phase I | Ipilimumab Nivolumab | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) | Completed | USA | NLD | ESP | 0 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01638676 | Phase Ib/II | Metformin + Vemurafenib | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | Recruiting | USA | 0 |
NCT01656642 | Phase I | Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Vemurafenib | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | Completed | USA | 0 |
NCT01657591 | Phase I | Vemurafenib + XL888 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | Completed | USA | 0 |
NCT01659151 | Phase II | Aldesleukin Fludarabine Vemurafenib | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT01667419 | Phase III | Vemurafenib | BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma | Completed | USA | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HRV | GBR | FRA | EST | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT01677741 | Phase I | Dabrafenib | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Completed | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 0 |
NCT01682083 | Phase III | Dabrafenib + Trametinib | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD) | Completed | USA | SWE | POL | NZL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
NCT01682213 | Phase II | Dabrafenib | Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation | Completed | USA | 0 |
NCT01683188 | Phase III | Aldesleukin + Vemurafenib | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma | Terminated | USA | 0 |
NCT01689974 | Phase II | Ipilimumab | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | Terminated | USA | 0 |
NCT01696045 | Phase II | Ipilimumab | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | Terminated | USA | GBR | FRA | ESP | DNK | DEU | BEL | 1 |
NCT01701037 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | Terminated | USA | 0 |
NCT01701674 | Phase I | Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | Active, not recruiting | USA | 0 |
NCT01703507 | Phase I | Ipilimumab | Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases | Completed | USA | 0 |
NCT01708941 | Phase II | Interferon alpha-2b Ipilimumab | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01721603 | Phase II | Dabrafenib | A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases | Terminated | USA | 0 |
NCT01726738 | Phase II | Dabrafenib + Trametinib | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | Completed | USA | 0 |
NCT01738139 | Phase I | Imatinib + Ipilimumab | Ipilimumab and Imatinib Mesylate in Advanced Cancer | Completed | USA | 0 |
NCT01740297 | Phase Ib/II | Ipilimumab Talimogene laherparepvec | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | Completed | USA | FRA | DEU | 0 |
NCT01754376 | Phase II | Aldesleukin + Vemurafenib | Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma | Terminated | USA | 0 |
NCT01763164 | Phase III | Dacarbazine Binimetinib | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | Completed | USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT01765543 | Phase I | Rifampin + Vemurafenib | A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | Completed | USA | HRV | BRA | 2 |
NCT01767454 | Phase I | Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | Completed | USA | 0 |
NCT01777776 | Phase Ib/II | Encorafenib Encorafenib + Ribociclib | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | Terminated | USA | NLD | CAN | AUS | 0 |
NCT01781026 | Phase II | Vemurafenib | Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | Completed | USA | 0 |
NCT01781572 | Phase Ib/II | Binimetinib + Ribociclib | A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | Completed | USA | NLD | ITA | DEU | AUS | 0 |
NCT01810016 | Phase I | Ipilimumab NY-ESO-1 peptide vaccine | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | Terminated | USA | AUS | 0 |
NCT01813214 | Phase II | Vemurafenib | The Effects of Vemurafenib on Immunity in Patients With Melanoma | Terminated | USA | 0 |
NCT01820364 | Phase II | Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib Encorafenib + Infigratinib Capmatinib + Encorafenib | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma | Terminated | USA | ESP | DEU | CHE | CAN | AUS | 0 |
NCT01826448 | Phase I | Pexidartinib + Vemurafenib | A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma | Terminated | USA | FRA | DEU | 0 |
NCT01827111 | Phase II | Ipilimumab + Nab-paclitaxel | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT01835184 | Phase I | Cabozantinib + Vemurafenib | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | Terminated | USA | 0 |
NCT01841463 | Phase Ib/II | Vemurafenib + Voruciclib | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation | Suspended | USA | 0 |
NCT01843738 | Phase I | Vemurafenib | Radiation Use During Vemurafenib Treatment | Withdrawn | USA | 0 |
NCT01844674 | Phase I | Tizanidine + Vemurafenib | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | Completed | USA | CYP | CAN | BRA | 1 |
NCT01876212 | Phase II | Dasatinib | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | Completed | USA | 0 |
NCT01876641 | Phase Ib/II | Decitabine + Vemurafenib | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib | Terminated | USA | 0 |
NCT01894672 | Phase II | Encorafenib | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | Completed | USA | 0 |
NCT01897116 | Phase I | Hydroxychloroquine + Vemurafenib | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | Completed | USA | 0 |
NCT01902173 | Phase Ib/II | Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | Active, not recruiting | USA | 0 |
NCT01904123 | Phase I | WP1066 | A Phase I Trial of WP1066 | Completed | USA | 0 |
NCT01909453 | Phase III | Vemurafenib Encorafenib Binimetinib + Encorafenib | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS) | Completed | USA | TUR | SWE | SVK | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUS | ARG | 8 |
NCT01940809 | Phase II | Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT01941927 | Phase II | Trametinib + Uprosertib | Trametinib With GSK2141795 in BRAF Wild-type Melanoma | Completed | USA | 0 |
NCT01942993 | Phase II | Vemurafenib | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | Terminated | USA | 0 |
NCT01943422 | Phase Ib/II | Interferon alpha-2b + Vemurafenib | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | Completed | USA | 0 |
NCT01946789 | Phase I | Nogapendekin alfa inbakicept | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01950195 | Phase I | Ipilimumab | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | Terminated | USA | 0 |
NCT01950390 | Phase II | Ipilimumab Bevacizumab + Ipilimumab | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01955460 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | Active, not recruiting | USA | 0 |
NCT01961115 | Phase II | Epacadostat MELITAC 12.1 Peptide Vaccine | INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Completed | USA | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01967823 | Phase II | Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | Completed | USA | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |
NCT01970358 | Phase I | NeoVax melanoma vaccine | A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | Completed | USA | 0 |
NCT01970527 | Phase II | Ipilimumab | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | Terminated | USA | 0 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT01978236 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | Terminated | USA | AUS | 0 |
NCT01988896 | Phase I | Atezolizumab + Cobimetinib | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | AUS | 2 |
NCT01989585 | Phase Ib/II | Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Active, not recruiting | USA | 0 |
NCT01993719 | Phase II | Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide | Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02009397 | Phase Ib/II | Sargramostim Ipilimumab | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | Completed | USA | 0 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02012231 | Phase Ib/II | PLX8394 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | Terminated | USA | 0 |
NCT02013804 | Phase I | MEDI0680 | A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies | Completed | USA | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02020707 | Phase I | Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery | Completed | USA | 0 |
NCT02027935 | Phase II | Aldesleukin Cyclophosphamide Ipilimumab | Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 | Completed | USA | 0 |
NCT02027961 | Phase Ib/II | Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | Completed | USA | ITA | FRA | CAN | 0 |
NCT02032810 | Phase I | Panobinostat Ipilimumab | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | Completed | USA | 0 |
NCT02036086 | Phase II | Cobimetinib + Vemurafenib | Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | Unknown status | CAN | 0 |
NCT02039947 | Phase II | Dabrafenib + Trametinib | Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUS | 0 |
NCT02043665 | Phase I | Coxsackievirus A21 | Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) | Completed | USA | GBR | AUS | 0 |
NCT02047747 | Phase II | Dacomitinib | A Phase II Study of Dacomitinib in Progressive Brain Metastases | Terminated | USA | 0 |
NCT02050321 | Phase II | Acitretin + Vemurafenib | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | Terminated | USA | 0 |
NCT02054520 | Phase II | Ipilimumab | Immunotherapy Study for Patients With Stage IV Melanoma | Terminated | USA | 0 |
NCT02065466 | Phase Ib/II | Bevacizumab + Nab-paclitaxel + Temozolomide | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | Withdrawn | USA | 0 |
NCT02068079 | Phase I | Trientine + Vemurafenib | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | Withdrawn | USA | 0 |
NCT02073123 | Phase Ib/II | Ipilimumab Indoximod | Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02089685 | Phase Ib/II | Ipilimumab Peginterferon alfa-2b Pembrolizumab | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | Completed | 0 | |
NCT02094872 | Phase II | Doxorubicin | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | Completed | USA | 0 |
NCT02097225 | Phase I | Dabrafenib + Onalespib + Trametinib | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT02097732 | Phase II | Ipilimumab | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | Terminated | USA | 0 |
NCT02107755 | Phase II | Ipilimumab | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02110355 | Phase Ib/II | KRT-232 + Trametinib Dabrafenib + KRT-232 + Trametinib Dabrafenib + Trametinib | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | Completed | USA | AUS | 0 |
NCT02112032 | Phase I | Peginterferon alfa-2b + Pembrolizumab | Treatment of Advanced Melanoma With MK-3475 and Peginterferon | Completed | USA | 0 |
NCT02115243 | Phase I | Ipilimumab | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | Completed | USA | 0 |
NCT02117362 | Phase I | Ipilimumab Belapectin | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02120222 | Phase I | Selinexor | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02126579 | Phase Ib/II | Poly ICLC Long peptide vaccine 7 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | Completed | USA | 0 |
NCT02129075 | Phase II | NeoVax melanoma vaccine CDX-301 Rasdegafusp alfa | CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma | Completed | USA | 0 |
NCT02130466 | Phase Ib/II | Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | Completed | 0 | |
NCT02138292 | Phase I | Digoxin + Trametinib | A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma | Completed | USA | 0 |
NCT02141542 | Phase I | Tremelimumab MEDI3617 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | Completed | USA | 0 |
NCT02142218 | Phase I | Nivolumab | Expanded Access Program With Nivolumab to Treat Melanoma | No longer available | USA | CAN | BRA | ARG | 2 |
NCT02143050 | Phase Ib/II | Dabrafenib + Metformin + Trametinib | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | Withdrawn | USA | 0 |
NCT02145910 | Phase I | Vemurafenib | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | Withdrawn | 0 | |
NCT02156804 | Phase II | Nivolumab | A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) | Completed | SWE | ROU | POL | NOR | NLD | LUX | ITA | IRL | HUN | GRC | GBR | FIN | ESP | DEU | CZE | CHE | BEL | AUT | 2 |
NCT02158520 | Phase II | Ipilimumab Bevacizumab + Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT02159066 | Phase II | Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib Binimetinib + Encorafenib + Infigratinib | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | Completed | USA | NLD | ITA | GBR | ESP | DEU | CHE | CAN | AUS | 0 |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | NLD | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02186249 | Phase III | Ipilimumab + Nivolumab | Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) | No longer available | USA | CAN | 0 |
NCT02196181 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02200562 | Phase Ib/II | Dabrafenib + Ipilimumab | Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma | Terminated | USA | 0 |
NCT02210104 | Phase I | Ipilimumab Cyclophosphamide | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | Withdrawn | 0 | |
NCT02224781 | Phase III | Ipilimumab + Nivolumab Dabrafenib + Trametinib | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | Active, not recruiting | USA | 0 |
NCT02230306 | Phase II | Cobimetinib + Vemurafenib | Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | Terminated | USA | 0 |
NCT02231775 | Phase II | Dabrafenib + Trametinib | Combi-Neo Study for Stage IV Melanoma | Active, not recruiting | USA | 0 |
NCT02257424 | Phase Ib/II | Dabrafenib + Hydroxychloroquine + Trametinib | Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM) | Completed | USA | 0 |
NCT02259231 | Phase Ib/II | Ipilimumab Nivolumab Omaveloxolone | RTA 408 Capsules in Patients With Melanoma - REVEAL | Completed | USA | 0 |
NCT02263508 | Phase Ib/II | Pembrolizumab Talimogene laherparepvec | MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma | Terminated | USA | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
NCT02263898 | Phase II | Binimetinib + Encorafenib | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | Withdrawn | USA | 0 |
NCT02272855 | Phase II | Canerpaturev + Ipilimumab | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma | Completed | USA | 0 |
NCT02296112 | Phase II | Trametinib | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | Completed | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02300935 | Phase I | Nab-paclitaxel + Trametinib | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | Withdrawn | USA | 0 |
NCT02302339 | Phase II | Glembatumumab vedotin | A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma | Terminated | USA | 0 |
NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
NCT02306850 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | Completed | USA | 0 |
NCT02307149 | Phase I | Coxsackievirus A21 Ipilimumab | Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma | Completed | USA | 0 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS | 0 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | NLD | FRA | 1 |
NCT02318771 | Phase I | Pembrolizumab | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02320058 | Phase II | Ipilimumab + Nivolumab | A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) | Completed | USA | 0 |
NCT02320305 | Phase I | MART-1 antigen GLA-SE + MART-1 antigen | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | Completed | USA | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02332668 | Phase Ib/II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | DEU | BRA | 1 |
NCT02334735 | Phase II | Poly ICLC Autologous Dendritic Cells Pulsed with MART-1 NY-ESO-1 peptide vaccine | A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | Completed | USA | 0 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02339324 | Phase I | Interferon alpha-2b Pembrolizumab | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | Completed | USA | 0 |
NCT02339571 | Phase II | Sargramostim Nivolumab Ipilimumab | Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | ISR | 0 |
NCT02360579 | Phase II | Lifileucel | Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144) | Active, not recruiting | USA | ITA | HUN | GBR | FRA | ESP | DEU | CHE | 0 |
NCT02362594 | Phase III | Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) | Active, not recruiting | 0 | |
NCT02381314 | Phase I | Ipilimumab + MGA271 | Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer | Completed | USA | 0 |
NCT02382549 | Phase I | 6MHP vaccine + Dabrafenib + Trametinib | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61) | Terminated | USA | 0 |
NCT02385669 | Phase Ib/II | 6MHP vaccine Ipilimumab | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | Terminated | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02388906 | Phase III | Nivolumab Ipilimumab | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) | Active, not recruiting | USA | SWE | ROU | POL | NOR | NLD | ITA | IRL | HUN | GRC | GBR | FRA | FIN | ESP | CZE | CHE | CAN | BEL | AUT | AUS | ARG | 4 |
NCT02400385 | Phase II | Nivolumab + Sunitinib | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | Withdrawn | USA | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | TUR | POL | NOR | NLD | LBN | ITA | HUN | FRA | ESP | DEU | CAN | 2 |
NCT02407171 | Phase Ib/II | Pembrolizumab | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | Completed | USA | 0 |
NCT02413827 | Phase Ib/II | Nivolumab + Varlilumab Rasdegafusp alfa Poly ICLC | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | Terminated | USA | 0 |
NCT02423863 | Phase II | Poly ICLC | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol | Completed | USA | 0 |
NCT02425306 | Phase Ib/II | Cyclophosphamide 6MHP vaccine Poly ICLC | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | Terminated | USA | 0 |
NCT02427893 | Phase III | Cobimetinib Vemurafenib | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | Withdrawn | USA | 0 |
NCT02428712 | Phase Ib/II | PLX8394 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02434354 | Phase I | Pembrolizumab | A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma | Completed | USA | 0 |
NCT02437136 | Phase Ib/II | Entinostat + Pembrolizumab | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma | Completed | USA | 0 |
NCT02452281 | Phase Ib/II | Vitespen Ipilimumab | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | Withdrawn | USA | 0 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02475213 | Phase I | MGA271 + Pembrolizumab | Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer | Completed | USA | 0 |
NCT02493361 | Phase II | Pembrolizumab IL-12 gene | Trial of pIL-12/MK-3475 in Metastatic Melanoma | Completed | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02500576 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab | MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2) | Completed | USA | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | NOR | ESP | 0 |
NCT02506153 | Phase III | Interferon alpha-2b Pembrolizumab | High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | Active, not recruiting | USA | IRL | CAN | 0 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02519322 | Phase II | Ipilimumab Nivolumab | Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma | Completed | USA | 0 |
NCT02521870 | Phase I | Pembrolizumab SD-101 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma | Terminated | USA | NZL | DEU | AUS | 0 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02553642 | Phase II | Nivolumab Ipilimumab | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Completed | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT02557321 | Phase Ib/II | PV-10 Pembrolizumab | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02565992 | Phase I | Coxsackievirus A21 + Pembrolizumab | Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma | Completed | USA | 0 |
NCT02574533 | Phase I | Pembrolizumab FANG vaccine | Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma | Completed | USA | 0 |
NCT02575404 | Phase I | Belapectin Pembrolizumab | GR-MD-02 Plus Pembrolizumab in Melanoma Patients | Completed | USA | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02576665 | Phase I | Toca FC + Vocimagene amiretrorepvec | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02587650 | Phase II | Ceritinib Capmatinib Regorafenib Entrectinib | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | Terminated | USA | 0 |
NCT02591654 | Phase I | Pembrolizumab | MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma | Terminated | USA | 0 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Completed | USA | 0 |
NCT02599402 | Phase III | Ipilimumab + Nivolumab Nivolumab | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | Completed | SWE | NOR | ITA | IRL | GBR | FRA | FIN | DEU | CHE | BEL | AUT | AUS | 0 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02608268 | Phase Ib/II | Spartalizumab Sabatolimab | Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | CHE | CAN | 4 |
NCT02617849 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | Active, not recruiting | CAN | 0 |
NCT02621021 | Phase II | Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin | A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | Suspended | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02637531 | Phase I | Pembrolizumab Eganelisib | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Unknown status | USA | 0 |
NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Completed | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02644967 | Phase Ib/II | IMO-2125 + Ipilimumab IMO-2125 + Pembrolizumab | A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Recruiting | AUS | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02652455 | Phase I | Nivolumab Aldesleukin + Cyclophosphamide + Fludarabine Urelumab | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | Completed | USA | 0 |
NCT02656706 | Phase II | Ipilimumab + Nivolumab | BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial | Active, not recruiting | USA | 0 |
NCT02659540 | Phase I | Ipilimumab + Nivolumab | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Completed | USA | 0 |
NCT02681549 | Phase II | Bevacizumab + Pembrolizumab | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02706353 | Phase Ib/II | Pembrolizumab + Sotigalimab | APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02711345 | Phase I | LTT462 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers | Terminated | USA | ESP | DEU | CHE | 2 |
NCT02714218 | Phase III | Ipilimumab + Nivolumab | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | Completed | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 1 |
NCT02716948 | Phase I | Nivolumab | Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | Completed | USA | 0 |
NCT02718066 | Phase Ib/II | Chidamide + Nivolumab | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02719015 | Phase Ib/II | Pembrolizumab + rAd-hCD40L | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | Withdrawn | 0 | |
NCT02721459 | Phase I | Cobimetinib + Vemurafenib + XL888 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | Active, not recruiting | USA | 0 |
NCT02723006 | Phase I | Nivolumab + Tovorafenib MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | Terminated | USA | 0 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
NCT02736123 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | Withdrawn | USA | 0 |
NCT02740920 | Phase II | Pembrolizumab | Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker | Terminated | CAN | 0 |
NCT02743819 | Phase II | Ipilimumab + Pembrolizumab | Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody | Active, not recruiting | USA | 0 |
NCT02748564 | Phase II | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Terminated | USA | 0 |
NCT02752074 | Phase III | Epacadostat + Pembrolizumab Pembrolizumab | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | Completed | USA | SWE | POL | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUS | 6 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02796352 | Phase II | Aldesleukin | A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study | Terminated | USA | 0 |
NCT02799095 | Phase I | ALKS 4230 | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | Completed | USA | POL | ESP | CAN | BEL | AUS | 1 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | FIN | ESP | DEU | CHE | BEL | 3 |
NCT02812693 | Phase Ib/II | Imatinib + Pembrolizumab | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | Withdrawn | 0 | |
NCT02816021 | Phase II | Azacitidine + Pembrolizumab | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02818023 | Phase I | Cobimetinib + Pembrolizumab + Vemurafenib | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Terminated | USA | 0 |
NCT02819843 | Phase II | Talimogene laherparepvec | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | Completed | USA | 0 |
NCT02823405 | Phase I | Pembrolizumab + X4P-001 | Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA) | Completed | USA | 0 |
NCT02839694 | Phase I | Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | Withdrawn | 0 | |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
NCT02857569 | Phase Ib/II | Ipilimumab + Nivolumab | A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT) | Completed | FRA | 0 |
NCT02858869 | Phase 0 | Pembrolizumab | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | Completed | USA | 0 |
NCT02870244 | Phase I | Autologous TIL 1383I TCR transduced T-cells | Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | Recruiting | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02889861 | Phase Ib/II | Tebentafusp | IMCgp100-401 Rollover Study | Terminated | USA | GBR | 0 |
NCT02897765 | Phase I | Nivolumab NEO-PV-01 + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Completed | USA | 0 |
NCT02908672 | Phase III | Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib | A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | Completed | USA | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | 3 |
NCT02910700 | Phase II | Nivolumab + Trametinib Dabrafenib + Nivolumab + Trametinib | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02915666 | Phase I | Dabrafenib + Digoxin + Trametinib | A Clinical Trial of Patients With Melanoma | Withdrawn | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | CHE | 0 |
NCT02935790 | Phase I | Citarinostat + Ipilimumab + Nivolumab | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | Completed | USA | 0 |
NCT02939300 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma | Completed | USA | 0 |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02961283 | Phase I | ASN003 | Study of ASN003 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02965716 | Phase II | Pembrolizumab + Talimogene laherparepvec | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Active, not recruiting | USA | 0 |
NCT02967692 | Phase III | Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i) | Completed | USA | SWE | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 6 |
NCT02970981 | Phase II | Ipilimumab + Nivolumab | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | Completed | USA | 0 |
NCT02974725 | Phase I | LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Terminated | USA | SWE | POL | ITA | ISR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT02974803 | Phase II | Dabrafenib + Trametinib | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | Terminated | CAN | 0 |
NCT02977156 | Phase I | Ipilimumab + JX-594 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) | Completed | FRA | 0 |
NCT02981303 | Phase II | Pembrolizumab + PGG beta-glucan | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02983006 | Phase I | DS-8273a + Nivolumab | Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | Completed | USA | 0 |
NCT02983045 | Phase Ib/II | Nivolumab + NKTR-214 | A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) | Completed | USA | POL | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
NCT02989064 | Phase I | MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers | Completed | USA | ESP | CAN | 0 | |
NCT02990416 | Phase Ib/II | A-dmDT390-bisFv(UCHT1) + Pembrolizumab | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | Unknown status | USA | 0 |
NCT03003676 | Phase I | Cyclophosphamide + ONCOS-102 + Pembrolizumab | A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade | Completed | USA | NOR | 0 |
NCT03005639 | Phase II | Cobimetinib + Vemurafenib | ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma | Withdrawn | USA | 0 |
NCT03021460 | Phase II | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03025256 | Phase I | Nivolumab | Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD) | Recruiting | USA | 0 |
NCT03026517 | Phase I | Dabrafenib + Phenformin + Trametinib | Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma | Active, not recruiting | USA | 0 |
NCT03033576 | Phase II | Ipilimumab Ipilimumab + Nivolumab | Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03047928 | Phase Ib/II | IO102-IO103 + Nivolumab | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma | Unknown status | DNK | 0 |
NCT03050060 | Phase II | Nelfinavir + Nivolumab | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | Terminated | USA | 0 |
NCT03068455 | Phase III | Nivolumab Ipilimumab Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Completed | USA | ROU | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 1 |
NCT03088176 | Phase I | Dabrafenib + Talimogene laherparepvec + Trametinib | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | Unknown status | USA | 0 |
NCT03089606 | Phase II | Pembrolizumab | Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker | Completed | USA | 0 |
NCT03092453 | Phase I | Cyclophosphamide + Pembrolizumab | Dendritic Cell Vaccination in Patients With Advanced Melamona | Active, not recruiting | USA | 0 |
NCT03098160 | Phase I | Evofosfamide + Ipilimumab | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | Unknown status | USA | 0 |
NCT03101254 | Phase Ib/II | Cobimetinib + LY3022855 + Vemurafenib | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | Completed | USA | 0 |
NCT03111901 | Phase Ib/II | Aldesleukin + Pembrolizumab | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer | Withdrawn | USA | 0 |
NCT03122522 | Phase II | Nivolumab Ipilimumab + Nivolumab | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | Active, not recruiting | USA | 0 |
NCT03126461 | Phase II | Ipilimumab + Nivolumab | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | Withdrawn | USA | 0 |
NCT03131908 | Phase Ib/II | GSK2636771 + Pembrolizumab | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | Active, not recruiting | USA | 0 |
NCT03132675 | Phase II | IL-12 gene + Pembrolizumab | pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment (PISCES) | Active, not recruiting | USA | ITA | CHE | CAN | AUS | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03149029 | Phase II | Dabrafenib + Pembrolizumab + Trametinib Pembrolizumab + Trametinib | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | Active, not recruiting | USA | 0 |
NCT03159117 | Phase I | PF-06688992 | Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma | Completed | USA | 0 |
NCT03161431 | Phase I | SX-682 Pembrolizumab + SX-682 | SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | Recruiting | USA | 0 |
NCT03161756 | Phase Ib/II | Denosumab + Nivolumab Denosumab + Ipilimumab + Nivolumab | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (CHARLI) | Unknown status | AUS | 0 |
NCT03166397 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | Recruiting | ISR | 0 |
NCT03175432 | Phase II | Atezolizumab + Bevacizumab | Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) | Active, not recruiting | USA | 0 |
NCT03178851 | Phase I | Atezolizumab Atezolizumab + Cobimetinib | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | Completed | USA | ESP | BRA | AUS | 3 |
NCT03179436 | Phase Ib/II | MK-1308 + Pembrolizumab MK-1308 | Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Completed | USA | SWE | POL | NZL | ITA | ISR | GRC | FRA | ESP | CAN | AUS | 5 |
NCT03192345 | Phase I | Cemiplimab + SAR439459 SAR439459 | A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | EST | ESP | DEU | CAN | BEL | AUS | 2 |
NCT03200847 | Phase Ib/II | Pembrolizumab + Tretinoin | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | Completed | USA | 0 |
NCT03207867 | Phase II | Spartalizumab + Taminadenant | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG | 3 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03236935 | Phase I | L-NMMA + Pembrolizumab | Phase Ib of L-NMMA and Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03239145 | Phase I | Pembrolizumab + Trebananib | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Active, not recruiting | USA | 0 |
NCT03241927 | Phase II | Pembrolizumab | Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | Terminated | USA | 0 |
NCT03259425 | Phase II | Canerpaturev + Nivolumab | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | Terminated | USA | 0 |
NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
NCT03272464 | Phase I | Dabrafenib + Itacitinib + Trametinib | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | Terminated | USA | 0 |
NCT03273153 | Phase III | Pembrolizumab Atezolizumab + Cobimetinib | A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | Terminated | USA | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | BEL | AUS | 2 |
NCT03276832 | Phase I | Imiquimod + Pembrolizumab | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | Active, not recruiting | USA | 0 |
NCT03277352 | Phase Ib/II | Epacadostat + INCAGN01876 + Pembrolizumab | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | Terminated | USA | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03301636 | Phase II | Indoximod + Nivolumab Indoximod + Pembrolizumab | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107) | Terminated | USA | 0 |
NCT03301896 | Phase I | LHC165 + Spartalizumab LHC165 | Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | ITA | ESP | DEU | BEL | 2 |
NCT03311308 | Phase I | Metformin + Pembrolizumab Pembrolizumab | A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | Recruiting | USA | 0 |
NCT03311334 | Phase I | Atezolizumab + DSP-7888 DSP-7888 + Nivolumab | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Terminated | USA | CAN | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03325101 | Phase Ib/II | Pembrolizumab | Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery | Completed | USA | 0 |
NCT03329846 | Phase III | Linrodostat + Nivolumab Nivolumab | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | Completed | USA | POL | NZL | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 1 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03332589 | Phase I | Dabrafenib + E6201 E6201 | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | Terminated | USA | 0 |
NCT03336606 | Phase I | Tavolimab | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | Active, not recruiting | USA | 0 |
NCT03340129 | Phase II | Ipilimumab + Nivolumab | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) | Recruiting | NOR | AUS | 0 |
NCT03341143 | Phase II | Pembrolizumab | Fecal Microbiota Transplant (FMT) in Melanoma Patients | Completed | USA | 0 |
NCT03347617 | Phase II | Pembrolizumab | Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma | Active, not recruiting | USA | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03374839 | Phase Ib/II | Aldesleukin + Nivolumab + tumor infiltrating lymphocytes | Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients (Nivo-TIL) | Unknown status | FRA | 0 |
NCT03384836 | Phase Ib/II | Pembrolizumab + Propranolol | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | Suspended | USA | 0 |
NCT03385486 | Phase I | TBX-3400 | Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors | Recruiting | USA | 0 |
NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Completed | USA | 0 |
NCT03396952 | Phase II | Ipilimumab + Pembrolizumab | Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma | Completed | USA | 0 |
NCT03407170 | Phase II | Pembrolizumab | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | Terminated | USA | 0 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03420508 | Phase II | Ensartinib | Treating Patients With Melanoma and ALK Alterations With Ensartinib | Active, not recruiting | USA | 0 |
NCT03425279 | Phase Ib/II | Mecbotamab Vedotin | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 2 |
NCT03425461 | Phase I | Ipilimumab + Pepinemab Nivolumab + Pepinemab | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | Terminated | USA | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03445533 | Phase III | Ipilimumab IMO-2125 + Ipilimumab | A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) | Terminated | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 0 |
NCT03448666 | Phase II | Pembrolizumab | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | Withdrawn | ITA | 0 |
NCT03455764 | Phase Ib/II | Dabrafenib + MCS110 + Trametinib | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | Completed | USA | 0 |
NCT03470922 | Phase II | Nivolumab + Relatlimab Nivolumab | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | Active, not recruiting | USA | SWE | ROU | POL | NZL | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT03474497 | Phase Ib/II | Aldesleukin + Pembrolizumab + Radiotherapy | Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | Recruiting | USA | 0 |
NCT03476174 | Phase II | Aldesleukin + Pembrolizumab | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | Terminated | USA | 0 |
NCT03484923 | Phase II | Ieramilimab + Spartalizumab Capmatinib + Spartalizumab Canakinumab + Spartalizumab | Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 0 |
NCT03501368 | Phase II | Ceritinib | Study of Ceritinib in Patients With Unresectable Melanoma | Active, not recruiting | USA | 0 |
NCT03502330 | Phase I | Cabiralizumab + Nivolumab + Sotigalimab Cabiralizumab + Sotigalimab | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | Completed | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03525795 | Phase Ib/II | CPI-1205 + Ipilimumab | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03526185 | Phase I | tumor infiltrating lymphocytes | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | Terminated | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03543969 | Phase I | Cobimetinib + Vemurafenib | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | Active, not recruiting | USA | 0 |
NCT03554083 | Phase I | Atezolizumab + Cobimetinib Atezolizumab + Cobimetinib + Vemurafenib | Vemurafenib, Cobimetinib, and Atezolizumab in Treating Participants With High-Risk Stage III Melanoma | Recruiting | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03563729 | Phase II | Pembrolizumab Binimetinib + Encorafenib Ipilimumab + Nivolumab Dabrafenib + Trametinib | Melanoma Metastasized to the Brain and Steroids (MEMBRAINS) | Recruiting | DNK | 0 |
NCT03565406 | Phase I | Ipilimumab + Mocetinostat + Nivolumab | A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | Terminated | USA | 0 |
NCT03567889 | Phase III | Daromun | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (Neo-DREAM) | Recruiting | USA | ESP | CHE | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03580382 | Phase Ib/II | CDX-3379 + Trametinib | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | Terminated | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03595683 | Phase II | EDP1503 + Pembrolizumab | Pembrolizumab and EDP1503 in Advanced Melanoma | Active, not recruiting | USA | 0 |
NCT03597282 | Phase I | Ipilimumab + Nivolumab Nivolumab + Sotigalimab Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC + Sotigalimab Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | Terminated | USA | 0 |
NCT03608020 | Phase Ib/II | BMX-001 | A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy | Terminated | USA | 0 |
NCT03611868 | Phase Ib/II | Alrizomadlin + Pembrolizumab Alrizomadlin | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT03617328 | Phase Ib/II | 6MHP vaccine + Montanide ISA 51 + Poly ICLC + Varlilumab 6MHP vaccine + Montanide ISA 51 + Poly ICLC | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65) | Completed | USA | 0 |
NCT03620019 | Phase II | Denosumab + Pembrolizumab Pembrolizumab | Denosumab + Pembrolizumab in Patients With Stage IV Melanoma | Completed | USA | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03633110 | Phase Ib/II | GEN-009 GEN-009 + Nivolumab | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | Completed | USA | 0 |
NCT03635983 | Phase III | Nivolumab Nivolumab + NKTR-214 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | Completed | USA | SWE | ROU | POL | NZL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT03637803 | Phase I | MRx0518 + Pembrolizumab | MRx0518 and Pembrolizumab Combination Study | Terminated | USA | 0 |
NCT03645928 | Phase II | Lifileucel + Pembrolizumab LN-145 LN-145 + Pembrolizumab | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Recruiting | USA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | 0 |
NCT03646617 | Phase II | Ipilimumab + Nivolumab | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | Recruiting | USA | 0 |
NCT03655756 | Phase I | IFx-Hu2.0 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | Completed | USA | 0 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Active, not recruiting | USA | POL | NZL | NLD | ITA | GBR | FRA | ESP | BRA | ARG | 2 |
NCT03679767 | Phase II | Retifanlimab | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Completed | USA | ROU | POL | ITA | HUN | FRA | ESP | AUT | 0 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03685890 | Phase Ib/II | Nivolumab | Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (NivoILP) | Recruiting | SWE | NLD | 0 |
NCT03698019 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery | Active, not recruiting | USA | 0 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | NZL | FRA | ESP | DNK | 1 |
NCT03712358 | Phase I | PVSRIPO | PVSRIPO for Patients With Unresectable Melanoma | Terminated | USA | 0 |
NCT03719131 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Rituximab | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | Active, not recruiting | USA | 0 |
NCT03719768 | Phase I | Avelumab | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | Active, not recruiting | USA | 0 |
NCT03724968 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | Terminated | USA | 0 |
NCT03727789 | Phase I | CBL0137 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Terminated | USA | 0 |
NCT03743766 | Phase II | Relatlimab Nivolumab + Relatlimab Nivolumab | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | Completed | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03757689 | Phase II | Pembrolizumab | Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma | Active, not recruiting | USA | 0 |
NCT03758781 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | Completed | USA | 0 |
NCT03765229 | Phase II | Entinostat + Pembrolizumab | An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | Completed | USA | 0 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT03769155 | Phase I | Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab Ipilimumab + Nivolumab + Pepinemab | VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma | Active, not recruiting | USA | 0 |
NCT03772899 | Phase I | Fecal microbiota | Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic) | Active, not recruiting | CAN | 0 |
NCT03776136 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | Completed | USA | SWE | ESP | CAN | AUS | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03815058 | Phase II | Autogene cevumeran + Pembrolizumab Pembrolizumab | A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma. | Active, not recruiting | USA | GBR | ESP | DEU | BEL | AUS | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03816332 | Phase I | Ipilimumab + Nivolumab + Prednisone + Tacrolimus | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03820986 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | Active, not recruiting | USA | SWE | POL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUT | AUS | 4 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |
NCT03834623 | Phase II | CC-122 + Nivolumab | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | Completed | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT03864042 | Phase I | Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | Completed | USA | NLD | ESP | CAN | BEL | 0 |
NCT03865212 | Phase I | VSV-IFNbetaTYRP1 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | Active, not recruiting | USA | 0 |
NCT03871348 | Phase I | SAR441000 Cemiplimab + SAR441000 | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Terminated | USA | NLD | FRA | ESP | DEU | BEL | 0 |
NCT03873818 | Phase II | Ipilimumab + Pembrolizumab | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | Active, not recruiting | USA | 0 |
NCT03878719 | Phase I | Binimetinib + Encorafenib | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | Terminated | ITA | 0 |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | ESP | DEU | 3 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03901573 | Phase Ib/II | Atezolizumab + NT-I7 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Terminated | USA | 0 |
NCT03903640 | Phase II | Ipilimumab + Nivolumab | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | Terminated | USA | 0 |
NCT03911869 | Phase II | Binimetinib + Encorafenib | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS) | Terminated | USA | ITA | BEL | AUS | ARG | 0 |
NCT03922880 | Phase I | ADI-PEG 20 + Ipilimumab + Nivolumab | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | Completed | USA | 0 |
NCT03925350 | Phase II | Niraparib | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | Unknown status | USA | 0 |
NCT03929029 | Phase I | Ipilimumab + NeoVax + Nivolumab | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | Active, not recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03949153 | Phase Ib/II | Ipilimumab + Nivolumab | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (CRIRIN) | Completed | FRA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03957551 | Phase Ib/II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT03958383 | Phase Ib/II | hu14.18-IL2 hu14.18-IL2 + Nivolumab hu14.18-IL2 + Ipilimumab + Nivolumab | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | Suspended | USA | 0 |
NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |
NCT03972046 | Phase II | Dabrafenib + Talimogene laherparepvec + Trametinib | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | Withdrawn | USA | 0 |
NCT03978611 | Phase I | Ipilimumab + Relatlimab | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | Terminated | USA | ITA | ESP | DEU | CAN | BEL | 0 |
NCT03979651 | Phase Ib/II | Hydroxychloroquine + Trametinib | MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma (CHLOROTRAMMEL) | Unknown status | FRA | 0 |
NCT03980314 | Phase Ib/II | Nivolumab | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | Completed | USA | ROU | POL | NZL | ITA | IRL | FRA | ESP | CAN | BRA | AUS | ARG | 2 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03991130 | Phase II | Aldesleukin + Nivolumab | High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03993678 | Phase Ib/II | IP-001 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | Recruiting | CHE | 0 |
NCT03997474 | Phase Ib/II | ATL001 + Nivolumab ATL001 | ATL001 in Patients With Metastatic or Recurrent Melanoma | Terminated | GBR | ESP | 0 |
NCT03999749 | Phase II | Nivolumab Ipilimumab + Nivolumab + Tocilizumab | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | Active, not recruiting | USA | 0 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04013854 | Phase II | Ipilimumab + Nivolumab Nivolumab | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | Active, not recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Completed | USA | 0 |
NCT04021420 | Phase Ib/II | Nivolumab | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (SONIMEL01) | Unknown status | FRA | 0 |
NCT04042506 | Phase II | Nivolumab | SBRT as a Vaccination for Metastatic Melanoma | Withdrawn | USA | 0 |
NCT04044859 | Phase I | afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Recruiting | USA | ESP | CAN | BEL | 0 |
NCT04052971 | Phase Ib/II | ABN401 | To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation | Recruiting | AUS | 1 |
NCT04059224 | Phase II | Dabrafenib + Trametinib | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT) | Completed | BEL | 0 |
NCT04059588 | Phase I | 2141 V-11 | A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin | Completed | USA | 0 |
NCT04060407 | Phase Ib/II | CD24Fc + Ipilimumab + Nivolumab | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI) | Withdrawn | USA | 0 |
NCT04068181 | Phase II | Pembrolizumab + Talimogene laherparepvec | Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) | Completed | USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CAN | AUS | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04074096 | Phase II | Binimetinib + Encorafenib + Pembrolizumab | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) | Active, not recruiting | FRA | 0 |
NCT04074967 | Phase Ib/II | Ipilimumab + Pexmetinib Nivolumab + Pexmetinib | Study of ARRY-614 Plus Either Nivolumab or Ipilimumab | Active, not recruiting | USA | 0 |
NCT04079166 | Phase II | Pembrolizumab + SCIB1 Ipilimumab + Nivolumab + SCIB1 | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | Recruiting | GBR | 0 |
NCT04083599 | Phase Ib/II | GEN1042 | GEN1042 Safety Trial in Subjects With Malignant Solid Tumors | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 4 |
NCT04091750 | Phase II | Cabozantinib + Ipilimumab + Nivolumab Cabozantinib + Nivolumab | Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | Suspended | USA | 0 |
NCT04093323 | Phase II | alphaDC1 + Celecoxib + Interferon alpha-2b + Rintatolimod Ipilimumab unspecified PD-L1 antibody unspecified PD-1 antibody | Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma | Recruiting | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04109456 | Phase I | BI 853520 + Cobimetinib BI 853520 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | Recruiting | USA | AUS | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04119024 | Phase I | Aldesleukin + Anti-IL13RA2 CAR-T cells + Cyclophosphamide + Fludarabine | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04123470 | Phase Ib/II | Atezolizumab + LOAd703 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | Completed | USA | SWE | 0 |
NCT04125719 | Phase I | Nivolumab + PVSRIPO | PVSRIPO in Combination With Nivolumab in Melanoma (PPD1) | Withdrawn | USA | 0 |
NCT04126876 | Phase II | IMO-2125 | A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma (INTRIM) | Recruiting | NLD | 0 |
NCT04129515 | Phase Ib/II | Pembrolizumab | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | Not yet recruiting | USA | 0 |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04139902 | Phase II | Cobolimab + Dostarlimab-gxly Dostarlimab-gxly | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Recruiting | USA | 0 |
NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | TUR | ISR | GBR | ESP | DNK | 5 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | GBR | AUS | 0 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Active, not recruiting | USA | SVK | AUS | 2 |
NCT04152863 | Phase II | Pembrolizumab Coxsackievirus A21 + Pembrolizumab | Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | Terminated | USA | NOR | ITA | ISR | FRA | ESP | DEU | AUS | 3 |
NCT04187833 | Phase II | Nivolumab + Talazoparib | Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes | Completed | USA | 0 |
NCT04190628 | Phase I | ABM-1310 ABM-1310 + Cobimetinib | Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04207086 | Phase II | Lenvatinib + Pembrolizumab Pembrolizumab | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe) | Active, not recruiting | AUS | 0 |
NCT04217473 | Phase I | TILT-123 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL) | Active, not recruiting | FRA | DNK | 0 |
NCT04219254 | Phase Ib/II | BI-1206 + Pembrolizumab | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Recruiting | USA | SWE | 0 |
NCT04221438 | Phase II | Binimetinib + Encorafenib | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | Active, not recruiting | USA | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04249843 | Phase I | BGB3245 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | Recruiting | USA | AUS | 0 |
NCT04250246 | Phase II | Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1) | Not yet recruiting | ITA | 0 |
NCT04270864 | Phase I | IMO-2125 + Ipilimumab + Nivolumab | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) | Terminated | FRA | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04291105 | Phase II | Cemiplimab + VSV-hIFNbeta-NIS | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Recruiting | USA | BRA | 0 |
NCT04294576 | Phase I | BJ-001 + Pembrolizumab BJ-001 | Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) | Active, not recruiting | USA | 0 |
NCT04303169 | Phase Ib/II | Pembrolizumab Pembrolizumab + Vibostolimab Coxsackievirus A21 + Pembrolizumab | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C) | Active, not recruiting | USA | ITA | ISR | FRA | CHE | AUS | 0 |
NCT04305041 | Phase Ib/II | MK-1308 + Pembrolizumab + Vibostolimab Lenvatinib + MK-1308 + Pembrolizumab | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A) | Active, not recruiting | USA | ITA | ISR | FRA | CHE | AUS | 0 |
NCT04305054 | Phase Ib/II | Pembrolizumab + Vibostolimab Pembrolizumab | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B) | Recruiting | USA | POL | ITA | ISR | HUN | GRC | FRA | ESP | CHE | AUS | ARG | 3 |
NCT04309409 | Phase III | Nivolumab | Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma (NivoMela) | Active, not recruiting | DEU | 0 |
NCT04310397 | Phase II | Dabrafenib + Trametinib Dabrafenib + Spartalizumab + Trametinib | Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | Terminated | USA | 0 |
NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Terminated | USA | NZL | ITA | 0 |
NCT04328844 | Phase I | IOA-244 | A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers | Active, not recruiting | ITA | GBR | 0 |
NCT04337931 | Phase II | Sotigalimab | A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma | Terminated | POL | ESP | 0 |
NCT04349436 | Phase Ib/II | RP1 | A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS) | Recruiting | USA | 0 |
NCT04364230 | Phase Ib/II | 6MHP vaccine + CDX-1140 + NeoAg-mBRAF + Poly ICLC | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Mel66) | Completed | USA | 0 |
NCT04370704 | Phase Ib/II | INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT04382664 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Sargramostim + UV1 Telomerase peptide vaccine | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | Completed | USA | NOR | GBR | BEL | 0 |
NCT04417621 | Phase II | LTT462 + LXH 254 Trametinib Ribociclib | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Active, not recruiting | USA | NOR | NLD | ITA | ISR | GBR | FRA | DEU | CHE | BEL | AUS | ARG | 0 |
NCT04418167 | Phase I | JSI-1187 Dabrafenib + JSI-1187 | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | Suspended | USA | 0 |
NCT04419532 | Phase I | DS-1055a | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 1 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04427306 | Phase II | Talimogene laherparepvec | Neoadjuvant T-VEC in High Risk Early Melanoma | Suspended | USA | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |
NCT04452214 | Phase I | Nidanilimab + Pembrolizumab | A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors | Completed | USA | 0 |
NCT04455503 | Phase Ib/II | EVX-02 + Nivolumab | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | Terminated | AUS | 0 |
NCT04462406 | Phase II | Pembrolizumab Nivolumab + Pembrolizumab Ipilimumab + Nivolumab Ipilimumab + Pembrolizumab Nivolumab | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | Recruiting | USA | 0 |
NCT04464759 | Phase Ib/II | Nivolumab Hydroxychloroquine + Ipilimumab + Nivolumab Hydroxychloroquine + Nivolumab | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (LIMIT) | Recruiting | USA | 0 |
NCT04478279 | Phase Ib/II | ST-101 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT04495257 | Phase I | Ipilimumab + Nivolumab + Sotigalimab | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | Active, not recruiting | USA | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Completed | USA | FRA | ESP | CAN | 0 |
NCT04511013 | Phase II | Ipilimumab + Nivolumab Binimetinib + Encorafenib + Nivolumab | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Recruiting | USA | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04526730 | Phase II | Nivolumab + Tavokinogene telseplasmid Nivolumab | Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | Active, not recruiting | USA | 0 |
NCT04527549 | Phase II | Dabrafenib + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | Terminated | USA | 0 |
NCT04543188 | Phase I | Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | Terminated | USA | ISR | CAN | 0 |
NCT04557956 | Phase Ib/II | Tazemetostat Dabrafenib + Tazemetostat + Trametinib | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | Recruiting | USA | 0 |
NCT04562129 | Phase II | Aldesleukin + Ipilimumab + Nivolumab | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | Recruiting | USA | 0 |
NCT04572451 | Phase I | BMS-986253 + Nivolumab | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04581382 | Phase I | Pembrolizumab Nivolumab | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | Active, not recruiting | USA | 0 |
NCT04598009 | Phase II | Binimetinib + Imatinib | Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | Recruiting | USA | 0 |
NCT04616248 | Phase I | CDX-1140 + CDX-301 + Poly ICLC | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04618393 | Phase Ib/II | EMB-02 | A Study of EMB-02 in Participants With Advanced Solid Tumors | Terminated | USA | AUS | 1 |
NCT04633902 | Phase II | Olaparib + Pembrolizumab | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | Recruiting | USA | 0 |
NCT04648826 | Phase Ib/II | Azacitidine + Bintrafusp alfa | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | Withdrawn | USA | 0 |
NCT04655157 | Phase Ib/II | Encorafenib + Ipilimumab + Nivolumab Binimetinib + Encorafenib + Ipilimumab + Nivolumab | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01) | Terminated | USA | 0 |
NCT04674683 | Phase III | Nivolumab Chidamide + Nivolumab | Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma | Active, not recruiting | USA | NZL | ITA | GBR | FRA | ESP | DEU | CZE | BRA | BEL | AUT | AUS | 5 |
NCT04688658 | Phase Ib/II | Duvelisib + Nivolumab | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | Active, not recruiting | USA | 0 |
NCT04695977 | Phase II | Nivolumab Nivolumab + Vidutolimod | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | Terminated | USA | 0 |
NCT04698187 | Phase II | Nivolumab + Vidutolimod | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | Terminated | USA | 0 |
NCT04700072 | Phase Ib/II | Lenvatinib + MK-1308A Lenvatinib + Pembrolizumab | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | Active, not recruiting | USA | ITA | ISR | FRA | ESP | CHE | AUS | 1 |
NCT04708418 | Phase II | Pembrolizumab Pembrolizumab + Vidutolimod | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma | Suspended | USA | 0 |
NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Suspended | USA | 0 |
NCT04720768 | Phase Ib/II | Binimetinib + Encorafenib + Palbociclib | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE) | Recruiting | AUS | 0 |
NCT04722575 | Phase II | Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib | Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM) | Active, not recruiting | ITA | 0 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Active, not recruiting | USA | ISR | ESP | 0 |
NCT04741997 | Phase I | Binimetinib + Encorafenib + Nivolumab Binimetinib + Encorafenib | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | Recruiting | USA | 0 |
NCT04759846 | Phase I | Binimetinib + Encorafenib | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | Withdrawn | ITA | ESP | CZE | 0 |
NCT04762225 | Phase I | RPTR-168 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma | Terminated | USA | 0 |
NCT04768881 | Phase II | Pembrolizumab + Selinexor | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Newly Diagnosed or Recurrent Advanced Melanoma | Terminated | USA | 0 |
NCT04772989 | Phase I | AB308 + Zimberelimab | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) | Active, not recruiting | USA | POL | ESP | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04789668 | Phase Ib/II | Bintrafusp alfa + Pimasertib | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Completed | USA | 0 |
NCT04809805 | Phase I | BAY2666605 | A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer | Terminated | USA | 0 |
NCT04819373 | Phase II | BDB001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04834973 | Phase Ib/II | Pembrolizumab + Tigilanol tiglate | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | Terminated | AUS | 0 |
NCT04837196 | Phase Ib/II | ASP7517 + Pembrolizumab ASP7517 | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Completed | USA | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04892017 | Phase Ib/II | DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib | A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors | Recruiting | USA | 0 |
NCT04894994 | Phase II | FLX475 + Ipilimumab | FLX475 in Combination With Ipilimumab in Advanced Melanoma | Terminated | USA | 0 |
NCT04898543 | Phase I | m-ceNK cells + Nogapendekin alfa inbakicept | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04899921 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trigriluzole | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | Terminated | USA | 0 |
NCT04901988 | Phase II | Nivolumab | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION) | Terminated | GBR | 0 |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Active, not recruiting | USA | 0 |
NCT04903119 | Phase I | Dabrafenib + Nilotinib + Trametinib | Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | Recruiting | USA | 0 |
NCT04913025 | Phase II | Pembrolizumab Nivolumab | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) | Recruiting | GBR | 0 |
NCT04913220 | Phase Ib/II | Cemiplimab + THOR-707 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT04913285 | Phase I | Binimetinib + Exarafenib Exarafenib | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Recruiting | USA | NLD | FRA | ESP | AUS | 3 |
NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Terminated | USA | 0 |
NCT04940299 | Phase II | Ipilimumab + Nivolumab + Tocilizumab | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | Active, not recruiting | USA | 0 |
NCT04949113 | Phase III | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) | Active, not recruiting | USA | NLD | AUS | 0 |
NCT04955743 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT04964375 | Phase I | ABSK043 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor | Unknown status | AUS | 0 |
NCT04967196 | Phase I | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT04971499 | Phase Ib/II | Dapansutrile + Pembrolizumab | A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma | Recruiting | USA | 0 |
NCT04985604 | Phase Ib/II | Pimasertib + Tovorafenib Tovorafenib | Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT04987996 | Phase II | Pembrolizumab Belapectin + Pembrolizumab | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | Withdrawn | USA | 0 |
NCT04988841 | Phase II | Ipilimumab + MaaT013 + Nivolumab | Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (PICASSO) | Recruiting | FRA | 0 |
NCT04993677 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 | A Study of SEA-CD40 Given With Other Drugs in Cancers | Active, not recruiting | USA | SWE | FRA | ESP | DEU | CAN | 0 |
NCT04995094 | Phase II | Pembrolizumab Pembrolizumab + PGG beta-glucan | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | Withdrawn | USA | 0 |
NCT04996823 | Phase II | Axitinib + Ipilimumab | Axitinib + Ipilimumab in Advanced Melanoma | Recruiting | USA | 0 |
NCT05002569 | Phase III | Nivolumab + Relatlimab Nivolumab | A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098) | Active, not recruiting | USA | SWE | ROU | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
NCT05026983 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | Recruiting | USA | 0 |
NCT05031494 | Phase II | Toripalimab-tpzi + YH003 Gemcitabine + Nab-paclitaxel + Toripalimab-tpzi + YH003 | A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | Active, not recruiting | USA | AUS | 0 |
NCT05034536 | Phase II | Pembrolizumab Infliximab + Pembrolizumab | Pembrolizumab + Infliximab for Metastatic Melanoma | Recruiting | USA | 0 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05060432 | Phase Ib/II | EOS-448 + Pembrolizumab EOS-448 + EOS100850 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT05068102 | Phase I | BI 770371 + Ezabenlimab Effi-DEM + Ezabenlimab | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | Recruiting | NLD | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05083481 | Phase Ib/II | ASP1570 | A Study of ASP1570 in Adults With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05091346 | Phase Ib/II | E7386 + Pembrolizumab | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | Completed | USA | GBR | ESP | 1 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05097378 | Phase II | Binimetinib + Encorafenib | Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM) | Unknown status | GBR | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05116202 | Phase Ib/II | RO7247669 Atezolizumab + Tiragolumab Ipilimumab + Nivolumab RO7247669 + Tiragolumab | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | Completed | USA | NLD | ITA | FRA | ESP | AUS | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05136196 | Phase II | Cabozantinib + Nivolumab | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Suspended | USA | 0 |
NCT05142592 | Phase I | IPG7236 | IPG7236 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05155033 | Phase II | Aldesleukin + Pembrolizumab | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT05155254 | Phase III | IO102-IO103 + Pembrolizumab Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUS | 1 |
NCT05169957 | Phase I | Ipilimumab + Nivolumab | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | Completed | USA | 0 |
NCT05176470 | Phase Ib/II | Cyclophosphamide + Fludarabine + Lifileucel + Pembrolizumab | Lifileucel and Pembrolizumab for the Treatment of Locally Advanced Stage IIIB-D Melanoma | Active, not recruiting | USA | 0 |
NCT05203172 | FDA approved | Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Recruiting | USA | SVK | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 4 |
NCT05208762 | Phase I | SGN-PDL1V | A Study of SGN-PDL1V in Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT05222932 | Phase I | Avelumab + TILT-123 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL) | Recruiting | USA | FIN | 0 |
NCT05229614 | Phase II | Pembrolizumab | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) | Recruiting | ITA | DEU | 0 |
NCT05234437 | Phase II | Tigilanol tiglate | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma | Terminated | AUS | 0 |
NCT05238883 | Phase I | HFB200301 HFB200301 + Tislelizumab | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05259696 | Phase Ib/II | E-602 E-602 + Pembrolizumab | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) | Active, not recruiting | USA | 0 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05275374 | Phase Ib/II | BI 882370 + Trametinib BI 882370 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) | Not yet recruiting | 0 | |
NCT05289193 | Phase II | Ipilimumab + Nivolumab | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | Recruiting | USA | 0 |
NCT05293496 | Phase I | MGC018 + MGD019 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05297565 | Phase III | Nivolumab BMS-986298 | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE) | Completed | USA | POL | ITA | GBR | ESP | BEL | AUS | 0 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05299580 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR) | Withdrawn | ITA | 0 |
NCT05309421 | Phase II | EVX-01 + Pembrolizumab | Study of EVX-01 Vaccine in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | Recruiting | AUS | 0 |
NCT05340621 | Phase Ib/II | Binimetinib + OKI-179 | NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | Active, not recruiting | USA | 0 |
NCT05341349 | Phase I | Ipilimumab + Nivolumab Pembrolizumab | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | Recruiting | USA | 0 |
NCT05352672 | Phase III | Cemiplimab Cemiplimab + Fianlimab Pembrolizumab | Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | Recruiting | USA | TUR | ROU | POL | NLD | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT05361174 | Phase Ib/II | IOV-4001 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Recruiting | USA | 0 |
NCT05370807 | Phase II | Regorafenib | A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (RegoMel) | Recruiting | BEL | 0 |
NCT05383170 | Phase Ib/II | Cypep-1 + Pembrolizumab | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst) | Completed | USA | NLD | ITA | FRA | ESP | 0 |
NCT05388877 | Phase I | Dabrafenib + E6201 | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma | Recruiting | USA | 0 |
NCT05393713 | Phase I | IMC-001 | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for the Treatment of In-Transit Melanoma, The Sofusa-2 Study | Active, not recruiting | USA | 0 |
NCT05398640 | Expanded access | Lifileucel | Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | Available | USA | 0 |
NCT05407675 | Phase Ib/II | BMS-986408 + Ipilimumab + Nivolumab BMS-986408 + Nivolumab BMS-986408 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CHE | CAN | 0 |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05418972 | Phase II | Nivolumab and relatlimab-rmbw | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II) | Recruiting | AUS | 0 |
NCT05419388 | Phase Ib/II | RO7247669 | A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma | Recruiting | TUR | SVK | POL | NZL | GRC | ESP | CZE | CAN | BRA | AUS | 0 |
NCT05428007 | Phase II | Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | Recruiting | USA | 0 |
NCT05470283 | Phase I | Acetazolamide + OBX-115 Cyclophosphamide + Fludarabine + Furosemide + Mesna | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT05483400 | Phase II | Atezolizumab + Tiragolumab | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) | Recruiting | NLD | 0 |
NCT05487235 | Phase I | Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | POL | NZL | ESP | CAN | BRA | AUS | ARG | 2 |
NCT05496192 | Phase II | Nivolumab BMS-986298 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | Withdrawn | ESP | DEU | 0 |
NCT05498792 | Phase I | CBL0137 + Ipilimumab + Nivolumab | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | Suspended | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Active, not recruiting | USA | AUS | 0 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05537740 | Phase I | BAY 3375968 + Pembrolizumab BAY 3375968 | A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | BEL | 2 |
NCT05538130 | Phase I | PF-07799544 Encorafenib + PF-07799544 PF-07284890 + PF-07799544 PF-07799544 + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05549297 | Phase II | Pembrolizumab + Tebentafusp Tebentafusp | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT05573035 | Phase I | LYL845 | A Study to Investigate LYL845 in Adults With Solid Tumors | Active, not recruiting | USA | 0 |
NCT05577182 | Phase I | INCA32459 | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | Active, not recruiting | USA | ITA | ESP | BEL | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05585320 | Phase Ib/II | IMM-1-104 | A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05588453 | Phase Ib/II | Temozolomide + TGF-beta-imprinted NK cells | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | Recruiting | USA | 0 |
NCT05598853 | Phase I | Ipilimumab + Nivolumab | Intrathecal Double Checkpoint Inhibition (IT-IO) | Recruiting | CHE | 0 |
NCT05608291 | Phase III | Pembrolizumab Cemiplimab + Fianlimab | A Study to Evaluate the Superiority of the Fianlimab and Cemiplimab Combination Compared to Pembrolizumab in Adult and Adolescent Patients With Completely Resected High-Risk Skin Cancer | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05625399 | Phase III | Nivolumab + Relatlimab | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) | Recruiting | USA | SWE | POL | NOR | ITA | ISR | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
NCT05629546 | Phase I | Nivolumab + Relatlimab | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | Recruiting | USA | 0 |
NCT05640193 | Phase I | Lifileucel | Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Asymptomatic Melanoma Brain Metastases | Active, not recruiting | USA | 0 |
NCT05652673 | FDA approved | Nivolumab | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | Recruiting | NLD | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05653661 | Phase I | AP-160 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05655312 | Phase Ib/II | [212Pb]VMT01 | MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma | Recruiting | USA | 0 |
NCT05668585 | Phase Ib/II | Cetuximab + CFT1946 CFT1946 + Trametinib CFT1946 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05669352 | Phase Ib/II | CA-4948 + Pembrolizumab | A Phase 1/2 Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases | Recruiting | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05691491 | Phase Ib/II | M1774 + Temozolomide | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Recruiting | USA | 0 |
NCT05695898 | Phase Ib/II | Izuralimab + XmAb22841 | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy | Active, not recruiting | USA | 0 |
NCT05704647 | Phase II | Nivolumab and relatlimab-rmbw | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | Recruiting | USA | 0 |
NCT05704933 | Phase I | Ipilimumab + Nivolumab | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Active, not recruiting | USA | 0 |
NCT05709821 | Phase Ib/II | Pembrolizumab IMM60 IMM60 + Pembrolizumab | IMM60 and Pembrolizumab in Melanoma and NSCLC | Terminated | USA | GBR | ESP | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05717140 | Phase II | Nivolumab + Sargramostim | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | Withdrawn | USA | 0 |
NCT05727904 | Phase III | Lifileucel + Pembrolizumab Pembrolizumab | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 0 |
NCT05746897 | Phase I | NM1F + Pembrolizumab NM1F | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05767879 | Phase II | Binimetinib + Encorafenib | (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | Recruiting | NLD | 0 |
NCT05779423 | Phase II | Ipilimumab + Nivolumab | Cryoablation+Ipilimumab+Nivolumab in Melanoma | Recruiting | USA | 0 |
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Active, not recruiting | USA | 0 |
NCT05789069 | Phase I | HFB200603 HFB200603 + Tislelizumab | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |
NCT05831995 | Phase I | ABM-168 | Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | Recruiting | USA | 0 |
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |
NCT05877430 | Phase Ib/II | CJRB-101 + Pembrolizumab | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | Recruiting | USA | 1 |
NCT05896839 | Phase Ib/II | Ipilimumab + Nivolumab + Prednisone + Sirolimus | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05907122 | Phase III | Nivolumab | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Resected Melanoma | Recruiting | USA | ROU | NLD | ITA | HRV | FRA | ESP | DEU | BRA | ARG | 13 |
NCT05909618 | Phase II | Crizanlizumab + Nivolumab Crizanlizumab | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (14) | Recruiting | ISR | 0 |
NCT05912244 | Phase II | IO102-IO103 + Nivolumab and relatlimab-rmbw | A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma | Recruiting | USA | 0 |
NCT05913388 | Phase II | Pembrolizumab GB1211 + Pembrolizumab | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05938296 | Phase I | oHSV2-PD-L1/CD3-BsAb | oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection | Recruiting | USA | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT06014086 | Phase I | PH-762 | Intratumoral PH-762 for Cutaneous Carcinoma | Recruiting | USA | 0 |
NCT06030037 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma | Not yet recruiting | USA | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |
NCT06035744 | Phase I | CLN-617 + Pembrolizumab | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06054555 | Phase III | ABP 206 Nivolumab | A Study to Evaluate ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | Recruiting | USA | TUR | ROU | NLD | LTU | ITA | HRV | FRA | EST | ESP | DEU | CZE | CAN | ARG | 12 |
NCT06060613 | Phase Ib/II | OBX-115 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06090266 | Phase Ib/II | Cemiplimab + OR502 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Recruiting | USA | 0 |
NCT06101134 | Phase II | BMS-986298 Nivolumab + Relatlimab + rHuPH20 Nivolumab and relatlimab-rmbw Nivolumab | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | Recruiting | USA | ITA | GRC | ESP | ARG | 1 |
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06108479 | Phase I | DF6215 | Study of DF6215 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |
NCT06112314 | Phase III | Nivolumab IMC-F106C + Nivolumab Nivolumab + Relatlimab | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301) | Recruiting | USA | SWE | ROU | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | BGR | AUT | AUS | ARG | 0 |
NCT06116461 | FDA approved | Nivolumab | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE) | Recruiting | NLD | 0 |
NCT06131398 | Phase I | AMG 355 + Pembrolizumab AMG 355 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Recruiting | USA | POL | NLD | FRA | ESP | CHE | CAN | AUS | 3 |
NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06151847 | Phase II | Cyclophosphamide + Fludarabine Lifileucel Aldesleukin | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |
NCT06171178 | Phase I | ASP1012 + Pembrolizumab ASP1012 | A Study of ASP1012 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06190249 | Phase I | Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | Suspended | USA | 0 |
NCT06208124 | Phase Ib/II | IMM-6-415 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06216938 | Phase I | RP1 | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | Recruiting | USA | 0 |
NCT06237881 | Phase Ib/II | Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06246916 | Phase III | Cemiplimab + Fianlimab Nivolumab + Relatlimab | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma | Recruiting | USA | 0 |
NCT06249048 | Phase Ib/II | Pembrolizumab + STX-001 STX-001 | Phase 1/2 Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Recruiting | USA | AUS | 0 |
NCT06270082 | Phase I | IK-595 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06295159 | Phase I | Nivolumab Nivolumab and relatlimab-rmbw Ipilimumab + Nivolumab | Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | Recruiting | USA | 0 |
NCT06305247 | Phase Ib/II | IPN01194 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Recruiting | USA | FRA | ESP | 0 |
NCT06326411 | Phase I | NST-628 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628) | Recruiting | USA | AUS | 0 |
NCT06332755 | Phase I | LB-LR1109 | Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109) | Recruiting | USA | 0 |
NCT06362369 | Phase Ib/II | 7HP349 + Ipilimumab + Nivolumab | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Recruiting | USA | 0 |
NCT06365619 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse) | Recruiting | USA | 0 |
NCT06395090 | Phase Ib/II | MK-7684A MK-4280 + Pembrolizumab Pembrolizumab + Vibostolimab MK-4280A | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | Recruiting | USA | 1 |
NCT06448364 | Phase I | PF-06801591 + PF-07329640 PF-07329640 Bevacizumab + PF-07329640 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR) | Terminated | USA | 1 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06521567 | Phase Ib/II | Cobolimab + Dostarlimab-gxly | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Not yet recruiting | USA | ITA | FRA | ESP | DNK | DEU | CZE | BRA | ARG | 1 |
NCT06545682 | Phase Ib/II | Alpelisib + Pembrolizumab | Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | Not yet recruiting | USA | 0 |
NCT06566092 | Phase I | Lifileucel LN-145 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Recruiting | USA | 0 |
NCT06580938 | Phase I | PF-07921585 PF-06801591 + PF-07921585 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Recruiting | USA | 0 |
NCT06626256 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + STIL101 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | Not yet recruiting | USA | 0 |
NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |
NCT06683755 | Phase Ib/II | Ipilimumab + Nivolumab + Relatlimab | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | Not yet recruiting | USA | 0 |